3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
3
Breast Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Multiple Myeloma
2
Carcinoma, Non-Small-Cell Lung
2
Tongue Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Tubular Adenocarcinoma
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Large B-Cell, Diffuse
1
Infections
1
Hemangioma, Cavernous, Central Nervous System
1
Hemangioma
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Gallbladder Cancer Unresectable
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Cancer-Related Condition
1
Cachexia
1
Brenner Tumor
1
Biliary Tract Neoplasms
1
Arthritis, Rheumatoid
1
Interventions
Gemcitabine
9
Oxaliplatin
6
Cisplatin
6
Capecitabine
6
durvalumab
4
apatinib
4
S 1 (combination)
4
Irinotecan
4
Immune Checkpoint Inhibitors
4
surufatinib
3
Injections
3
Drug Therapy
3
pembrolizumab
2
lenvatinib
2
camrelizumab
2
Taxes
2
Leucovorin
2
Fluorouracil
2
Docetaxel
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
toripalimab
1
taxane
1
spartalizumab
1
sintilimab
1
regorafenib
1
manganese chloride
1
irinotecan sucrosofate
1
gimeracil
1
envafolimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Biliary Tract Neoplasms
×
Observation
×
Clear all
NCT04333927
2020-06-23
ACCORD
Sun Yat-sen University
Phase 2
Unknown
92 enrolled